BioAge Labs
Therapies targeting aging biology to treat cardiometabolic disease
- Sector
- Biotech
- Headquarters
- RICHMOND, CA
- Latest Form D
- $194M, Feb 2024
- Total capital
- $194M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $194M
- 1 Form D · last Feb 2024
- 32 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 11
- 29 pending · first 2021
- Rank in peer group#156 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$194M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#156 · top 11%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Dov GoldsteinExecutive OfficerNamed in SEC Form D filings
- Eric MorgenDirectorNamed in SEC Form D filings
- James HealyDirectorNamed in SEC Form D filings
- Jason ColomaDirectorNamed in SEC Form D filings
- Kristen FortneyExecutive Officer, DirectorNamed in SEC Form D filings
- Patrick EnrightDirectorNamed in SEC Form D filings
Show all 8 people
- Rehka HemrajaniDirectorNamed in SEC Form D filings
- Vijay PandeDirectorNamed in SEC Form D filings
What it has protected
USPTO · 11 granted of 40- PendingInhibitors Of NLRP3 InflammasomeUSPTOApplication 19647164
- PendingInhibitors Of NLRP3 InflammasomeUSPTOApplication 19551148
- GrantedInhibitors Of NLRP3 InflammasomeUSPTOUS 12,673,920
Show all 40 patent records
- Inhibitors Of NLRP3 InflammasomeSep 17, 2026 · Application 19647164Pending
- Inhibitors Of NLRP3 InflammasomeAug 27, 2026 · Application 19551148Pending
- Inhibitors Of NLRP3 InflammasomeJul 7, 2026 · US 12,673,920Granted
- Inhibitors Of NLRP3 InflammasomeMay 14, 2026 · Application 19363281Pending
- Inhibitors Of NLRP3 InflammasomeDec 30, 2025 · US 12,509,459Granted
- Inhibitors Of NLRP3 InflammasomeSep 23, 2025 · US 12,421,196Granted
- NLRP3 Variants & Library Screen for NLRP3 Inhibitors with the SameMay 15, 2025 · Application 18906535Pending
- N-oxide Inhibitors Of NLRP3 InflammasomeMar 20, 2025 · Application 18896259Pending
- Crystalline And Salt Forms Of An NLRP3 InhibitorMar 13, 2025 · Application 18882356Pending
- Inhibitors Of NLRP3 InflammasomeFeb 4, 2025 · US 12,215,087Granted
- Combination Therapy Of Apelin Receptor Agonist And GLP-1 Receptor Agonist For Treating A Disease Or Condition Associated With Weight GainNov 7, 2024 · Application 18754784Pending
- N-oxide Inhibitors Of NLRP3 InflammasomeOct 29, 2024 · US 12,129,251Granted
- Apelin Receptor Modulators for Treating Age-Related Muscle ConditionsAug 1, 2024 · Application 18286070Pending
- Apelin Receptor Modulators For Treating Muscle ConditionsApr 18, 2024 · Application 18373880Pending
- Indazole And Pyrazolopyridine Compounds As Inhibitors Of NLRP3 InflammasomeApr 11, 2024 · Application 18470105Pending
- Survival Prediction Using Metabolomic ProfilesMar 28, 2024 · Application 18295848Pending
- Apelin Receptor Modulators For Treatment Of A Disorder Or Disease Associated With Bbb PermeabilityFeb 8, 2024 · Application 18326934Pending
- Survival Prediction Using Metabolomic ProfilesJan 23, 2024 · US 11,881,311Granted
- N-oxide Inhibitors Of NLRP3 InflammasomeOct 17, 2023 · US 11,787,805Granted
- Inhibitors Of NLRP3 InflammasomeJul 25, 2023 · US 11,708,334Granted
- RAGE Fusion Proteins with Improved Stability and Ligand Binding Affinity and Uses ThereofJul 6, 2023 · Application 18146223Pending
- RAGE Fusion Proteins with Improved Stability and Ligand Binding Affinity and Uses ThereofDec 27, 2022 · US 11,535,661Granted
- Survival Prediction Using Methylomic ProfilesSep 20, 2022 · US 11,445,981Granted
- Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors For Treating Aging-related ConditionsNov 18, 2021 · Application 17242612Pending
- RAGE Fusion Proteins with Improved Stability and Ligand Binding Affinity and Uses ThereofJun 24, 2021 · Application 17127659Pending
- RAGE Fusion Proteins with Improved Stability and Ligand Binding Affinity and Uses ThereofFeb 9, 2021 · US 10,913,784Granted
- Drug Repurposing Based On Deep Embeddings Of Gene Expression ProfilesApr 18, 2019 · Application 16160457Pending
- Methods Of Treating A Disease Or Condition Associated With Weight GainApplication 63654827Pending
- Methods Of Treating A Disease Or Condition Associated With Weight GainApplication 63654854Pending
- Methods Of Treating A Disease Or Condition Associated With Weight GainApplication 63654771Pending
- Methods Of Treating A Disease Or Condition Associated With Weight GainApplication 63657076Pending
- Methods Of Treating A Disease Or Condition Associated With Weight GainApplication 63705017Pending
- Methods Of Treating A Disease Or Condition Associated With Weight GainApplication 63744163Pending
- Methods Of Treating A Disease Or Condition Associated With Weight GainApplication 63706557Pending
- Inhibitors Of NLRP3 InflammasomeApplication 63656967Pending
- Inhibitors Of NLRP3 InflammasomeApplication 63708034Pending
- Methods Of Treating A Disease Or Condition Associated With Weight GainApplication 63744164Pending
- Methods Of Treating A Disease Or Condition Associated With Weight GainApplication PCTUS2025023529Pending
- Methods Of Treating A Disease Or Condition Associated With Weight GainApplication 63667052Pending
- Methods Of Treating A Disease Or Condition Associated With Weight GainApplication 63667116Pending
Related companies, and why
- TrueBinding, Inc.Similar federal contract value in Biotech · null in contracts
- Bright Peak TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Cognito Therapeutics Group, Inc.Similar federal contract value in Biotech · null in contracts
- Janux TherapeuticsSimilar federal contract value in Biotech · null in contracts
- NewLimit, Inc.Similar federal contract value in Biotech · null in contracts
- GondolaBioSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .